The pharmaceutical and healthcare sector is one of the world’s most vital and innovative.
Against a backdrop of technological change and an increasing and aging population, we partner with our clients to help them achieve their goals, capitalise on opportunities and navigate uncertainty.
Combining deep scientific, technical and strategic knowledge we help our clients by providing the commercial nous, experience and range of services that only a large international professional services firm can offer, to anticipate and deliver innovative and value-enhancing solutions.
Recent Experience
Genus Plc
Advising Genus, a UK listed animal genetics company, on its strategic partnership with Beijing Capital Agribusiness Co. Ltd (BCA) to research, develop, register and market pigs resistant to Porcine Reproductive and Respiratory Syndrome virus (PRRSv) in China
Impilo
Advising Impilo, a Nordic-based investment company that focuses exclusively on investments in healthcare companies active in the areas of pharmaceuticals, medical technology, healthcare services and other health-related areas, on its leveraged buy-outs of The Fertility Partnership and Viva Neo - leading European providers of fertility services, ultrasound pregnancy scans and hormone treatments
Hoffmann La-Roche AG and Roche Products Limited (Roche)
Advising F. Hoffmann La-Roche AG and Roche Products Limited (Roche) in a significant High Court victory against Pfizer, in an action concerning Avastin®, Roche's blockbuster treatment for various forms of cancer. The action centred on whether a UK court should grant a form of negative declaratory relief known as an "Arrow declaration" in circumstances where our client had no relevant patent rights in the UK, and the claimant (Pfizer) intended to use the declarations and judgment solely for the purposes of influencing foreign courts.
Mylan Laboratories
Advising in its significant victory in a SIAC arbitration commenced by Phosphagenics in Singapore arising from licensing and research agreements, in which Phosphagenics claimed damages of over US$ 300 million
Aurobindo Pharma
Advising on its acquisition of Apotex's commercial operations across five European countries. The transaction includes a portfolio of over 200 prescription drugs and 88 OTC products and an additional pipeline of over 20 products
A global innovator pharmaceuticals company
Advising in an ICC arbitration seated in Singapore. This concerned a dispute with another global pharmaceuticals company arising out of a co-promotion agreement. Following a two-week merits hearing, our client won a significant award.
Insights and updates
